BI
TNGX icon

BVF Inc’s Tango Therapeutics TNGX Stock Holding History

BVF Inc’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-800,000
Closed -$8.9M – 74
2021
Q1 		$8.9M Hold
800,000
– – 0.33% 52
2020
Q4 		$9.15M Hold
800,000
– – 0.36% 47
2020
Q3 		$8.29M Buy
+800,000
New +$8.17M 0.45% 48

Other funds holding TNGX

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc's TNGX Position: Q2 2021 in Review

BVF Inc sold out of Tango Therapeutics (TNGX) in Q2 2021, closing a stake of 800,000 shares — an estimated $8.9M sold.

BVF Inc first reported a position in TNGX in Q3 2020 and held it in 3 quarters. The position peaked at $9.15M in Q4 2020. 31 funds tracked by Wall St. Rank hold TNGX as of Q2 2021.

  • BVF Inc reported no remaining Tango Therapeutics position as of Q2 2021 after selling out during the quarter.
  • BVF Inc sold 800,000 Tango Therapeutics shares in Q2 2021, an estimated $8.9M.
  • BVF Inc first reported a position in Tango Therapeutics in Q3 2020 and held it in 3 quarters.
  • BVF Inc's Tango Therapeutics position peaked at $9.15M in Q4 2020.
  • 31 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2021.

Based on BVF Inc's 13F filing for Q2 2021, filed 16 Aug 2021.